{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:54:03Z","timestamp":1782442443341,"version":"3.54.5"},"reference-count":16,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.nmd.2018.08.002","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T03:05:58Z","timestamp":1533870358000},"page":"965-968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Enzyme replacement therapy with alglucosidase alfa in a late-onset Pompe disease patient during pregnancy"],"prefix":"10.1016","volume":"28","author":[{"given":"Miguel","family":"Oliveira Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresinha","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Concei\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nmd.2018.08.002_bib0001","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/mus.21393","article-title":"Diagnostic criteria for late-onset (childhood and adult) Pompe disease","volume":"40","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2018.08.002_bib0002","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1750-1172-7-88","article-title":"Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study","volume":"7","author":"Van der Beek","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2018.08.002_bib0003","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1750-1172-8-49","article-title":"Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study","volume":"8","author":"Gungor","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.nmd.2018.08.002_bib0004","doi-asserted-by":"crossref","DOI":"10.1111\/ene.13285","article-title":"European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience","volume":"24","author":"van der Ploeg","year":"2017","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.nmd.2018.08.002_bib0005","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.nmd.2018.08.002_bib0006","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ymgme.2011.09.012","article-title":"First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease","volume":"104","author":"de Vries","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.nmd.2018.08.002_bib0007","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.nmd.2012.11.006","article-title":"Pregnancy during enzyme replacement therapy for late-onset acid maltase deficiency","volume":"23","author":"Zagnoli","year":"2013","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"10.1016\/j.nmd.2018.08.002_bib0008","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.nmd.2016.02.016","article-title":"Multidisciplinary care allowing uneventful vaginal delivery in a woman with Pompe disease","volume":"26","author":"Perniconi","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"10.1016\/j.nmd.2018.08.002_bib0009","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.nmd.2017.06.556","article-title":"Treatment with enzyme replacement therapy during pregnancy in a patient with Pompe disease","volume":"27","author":"Holbeck-Brendel","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2018.08.002_bib0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jns.2017.01.068","article-title":"Alglucosidase alfa therapy for Pompe disease in pregnancy - Case report","volume":"375","author":"Klos","year":"2017","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1016\/j.nmd.2018.08.002_bib0011","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2014.03.010","article-title":"Pregnancy and delivery in women with Pompe disease","volume":"112","author":"Karabul","year":"2014","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2018.08.002_bib0012","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bcmd.2016.10.003","article-title":"Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey","volume":"68","author":"Lau","year":"2018","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"10.1016\/j.nmd.2018.08.002_bib0013","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/jog.12254","article-title":"Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease","volume":"40","author":"Elstein","year":"2014","journal-title":"J Obstet Gynaecol Res"},{"issue":"2","key":"10.1016\/j.nmd.2018.08.002_bib0014","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1447-0756.2009.01164.x","article-title":"Treatment with agalsidase beta during pregnancy in Fabry disease","volume":"36","author":"Politei","year":"2010","journal-title":"J Obstet Gynaecol Res"},{"issue":"1","key":"10.1016\/j.nmd.2018.08.002_bib0015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejogrb.2009.01.007","article-title":"Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease","volume":"144","author":"Kalkum","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.nmd.2018.08.002_bib0016","series-title":"Proceedings of the European medicines agency\/EMA","article-title":"Myozyme: European public assessment report \u2014 product information: Annex 1 Summary of product characteristics","year":"2018"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896618302037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896618302037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:08:02Z","timestamp":1760774882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896618302037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0960896618302037"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2018.08.002","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enzyme replacement therapy with alglucosidase alfa in a late-onset Pompe disease patient during pregnancy","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2018.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}